S&P 500 Healthcare Sector SEC Filings — March 19, 2026

19-03-2026

Assembly Biosciences, Inc., a biotechnology company focused on antivirals for serious viral diseases, filed an S-3 shelf registration statement on March 19, 2026, incorporating its 10-K for the year ended December 31, 2025, to enable future securities offerings for general corporate purposes. Key highlights include Gilead Sciences exercising its option in December 2025 to license the HPI program (ABI-1179 and ABI-5366) and positive Phase 1 interim/topline data readouts in 2025 for multiple candidates (1179, 5366, 4334, 6250), with no reported setbacks but standard forward-looking risks around clinical success and funding. Authorized capital includes 150M common shares and 5M preferred shares.

• ·Gilead option exercised December 2025 for HPI program including ABI-1179 and ABI-5366.
• ·Clinical data readouts: ABI-1179 Phase 1a/b interim (Feb & Dec 2025), ABI-5366 Phase 1a/b interim weekly/monthly (Aug & Dec 2025), ABI-4334 Phase 1b topline (June 2025), ABI-6250 Phase 1a interim (Aug 2025).
• ·NNPI program: ABI-7423 identified Dec 2024, transitioned to ABI-7272 Oct 2025, now in regulatory filing-enabling studies.
• ·Principal office: Two Tower Place, 7th Floor, South San Francisco, CA 94080.
• ·Incorporated October 7, 2005 (originally South Island Biosciences, Inc.); acquired Assembly Pharmaceuticals July 11, 2014; name change from Ventrus Biosciences.

19-03-2026

Signet Jewelers reported full year Fiscal 2026 sales of $6.81B, up 1.6% YoY with SSS growth of 1.3% and adjusted operating income of $515.0M, up from $498.1M in FY25, driven by AUR increases of 7% and gross margin expansion. However, Q4 sales were nearly flat at $2.35B with SSS declining 0.7% YoY, adjusted operating income fell to $327.3M from $355.5M, and gross margin rate declined 60 bps due to merchandise margin pressure and fixed cost deleverage. Fiscal 2027 guidance projects sales of $6.6-6.9B with SSS ranging from -1.25% to +2.5%, alongside a quarterly dividend increase to $0.35 per share.

• ·Cash flow from operations FY26: $678.8M, up from $590.9M in FY25
• ·Capital expenditures FY26: $153.5M
• ·Total liquidity ~$2.0B as of Jan 31, 2026
• ·Q1 FY27 guidance: sales $1.53-1.57B, SSS 0.5-2.5%, adjusted operating income $66-77M
• ·FY27 guidance: adjusted operating income $470-560M, adjusted EBITDA $655-745M, adjusted diluted EPS $8.80-10.74
• ·FY27 capex planned $150-180M, net sq ft decrease low single digits
• ·Non-cash impairments FY26: $91.3M (largely digital brands), Q4 $6.6M (Diamonds Direct)
• ·Share repurchase authorization remaining: $518M
• ·Recognized as one of 2026 World’s Most Ethical Companies by Ethisphere

19-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 19, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX's RAD Books Hundreds of SARA Licenses as Customers Expand After Initial Deployment.' The press release is furnished as Exhibit 99.1 and is not deemed filed or material.

• ·Filed by newsfilecorp.com
• ·Registrant details: Nevada incorporation, Commission File Number 000-55079, IRS Employer Identification No. 27-2343603, principal offices at 10800 Galaxie Avenue, Ferndale, Michigan 48220

19-03-2026

News Corporation filed an 8-K on March 19, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program for Class A (NWSA) and Class B (NWS) common stock. The program authorizes repurchases up to $1B in aggregate, with daily ASX disclosures required for any transactions; Exhibits 99.1 and 99.2 contain the specific details. No actual repurchase volumes or impacts were detailed in the filing.

• ·Securities traded on The Nasdaq Global Select Market.
• ·Event date: March 18, 2026; Filing date: March 19, 2026.

19-03-2026

Aptose Biosciences Inc. filed an 8-K on March 19, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing the issuance of a press release dated March 19, 2026, attached as Exhibit 99.1. The press release content is not detailed in the filing body and is not deemed 'filed' under Section 18 of the Exchange Act. No financial or operational metrics are disclosed in the 8-K.

19-03-2026

SELLAS Life Sciences reported FY2025 financial results with R&D expenses decreasing 16% YoY to $16.0M and G&A expenses nearly flat at $12.3M (down 1% YoY), resulting in a narrowed net loss of $26.9M ($0.25/share) versus $30.9M ($0.50/share) in FY2024, bolstered by cash of $71.8M at year-end and additional $42.6M from warrant exercises in Q1 2026. Clinical programs advanced with 72 events reached in the Phase 3 REGAL trial for GPS (nearing the 80-event threshold for final analysis) and positive Phase 2 SLS009 data in r/r AML showing 46% ORR. However, the company continues to incur net losses, and G&A expenses showed minimal decline.

• ·Phase 2 SLS009 r/r AML: mOS 8.9 months in least pretreated cohort (vs expected 2.6 months); no DLTs or treatment-related deaths.
• ·REGAL trial: event-driven with 80 events required for final analysis; 72 events as of Dec 26, 2025.
• ·Preclinical SLS009: significant survival benefit in T-PLL model vs VEN alone (ESMO 2025); AACR 2026 poster on apoptosis in AML cell lines April 21, 2026.
• ·Warrant proceeds 2025: $54.6M from specific warrants ($23.6M Jan 2025 + $31.0M 2024 issues) + $12.6M others.

19-03-2026

Zions Bancorporation, N.A.'s 2026 proxy statement outlines the annual shareholder meeting on May 1, 2026, proposing the election of 11 directors (82% independent), ratification of Ernst & Young LLP as auditors for fiscal 2026, and an advisory vote approving 2025 named executive officer compensation, while recommending against a shareholder proposal on risks from policy-customer misalignment. Governance highlights include 100% independent standing committee membership, 45% board diversity, average director age of 66 and tenure of 12.5 years, and a CEO pay ratio of 64:1. No significant declines or flat metrics noted in governance disclosures.

• ·Record date: March 2, 2026
• ·Annual meeting location: Zions Bank Building Founders Room, 18th Floor, One South Main Street, Salt Lake City, Utah 84133
• ·Average director tenure: 12.5 years
• ·Average director age: 66
• ·CEO pay ratio: 64:1
• ·Shareholder right to call special meeting: by holders of 51% of votes entitled to be cast

19-03-2026

CVS Health Corporation elected John E. Gallina, former Executive Vice President and CFO of Elevance Health, Inc., to its Board of Directors effective March 19, 2026. Mr. Gallina, determined to be independent, was appointed to the Audit Committee and designated an 'audit committee financial expert' under SEC rules. His compensation will align with other non-employee directors, prorated from commencement.

• ·Mr. Gallina, age 66, served as CFO of Elevance from June 2016 through November 1, 2023, then as EVP and Advisor to the CEO until May 2024.
• ·Mr. Gallina holds a bachelor’s degree in business administration from The Ohio State University and is a certified public accountant.
• ·Director compensation practices described in CVS Health’s annual proxy statement filed April 4, 2025.

19-03-2026

Evofem Biosciences, Inc. (Buyer) and Windtree Therapeutics, Inc. (Supplier) mutually terminated their License and Supply Agreement (dated March 20, 2025, as amended) effective March 13, 2026, because Windtree failed to establish manufacturing capabilities for Evofem's Phexxi product. No termination fees are due to either party, with each bearing their own costs, but Windtree must immediately cease using Evofem's IP and return all confidential information and assets. This termination eliminates the supply arrangement without further obligations, potentially disrupting Evofem's Phexxi production.

• ·Agreement governed by Delaware law with exclusive jurisdiction in Delaware courts.
• ·Certain sections of the original License and Supply Agreement (per Section 11.6) survive termination.

19-03-2026

First Commonwealth Financial Corporation issued a notice of availability of proxy materials for its 2026 Annual Shareholders’ Meeting on April 28, 2026, at 1:00 P.M. ET, held virtually. Key proposals include the election of 12 director nominees, ratification of Ernst & Young LLP as independent auditors for 2026, and an advisory vote on named officer compensation, with the Board recommending a vote FOR all items. Shareholders must access materials online at www.envisionreports.com/FCF or request paper copies by April 16, 2026.

• ·Virtual attendance via https://meetnow.global/MQPU7JP using 15-digit control number.
• ·Paper copy requests via www.envisionreports.com/FCF, 1-866-641-4276, or investorvote@computershare.com must be received by April 16, 2026.
• ·Includes 2025 Annual Meeting Minutes, 2025 Annual Report, and 2026 Proxy Statement available online.

19-03-2026

ACCESS Newswire Inc. reported FY2025 revenue of $22.6M, down 2% YoY from $23.1M, with gross margin slightly improving to $17.3M (77% of revenue) from $17.4M (76%). Operating loss narrowed significantly to $1.9M from $16.3M, primarily due to impairment losses dropping to $0.3M from $14.2M, leading to Adjusted EBITDA growth of 78% to $3.2M; however, net cash from operations fell to $0.6M from $3.2M and free cash flow declined to $0.4M from $2.5M.

• ·Non-GAAP net income FY2025: $2.2M ($0.57 per diluted share) vs FY2024: $0.7M ($0.19 per diluted share).
• ·Adjusted free cash flow FY2025: $1.3M vs FY2024: $2.8M.
• ·Outlook includes expanding products, customer base, newswire distribution, technology investments, strategic acquisitions, and sustainable growth.

19-03-2026

Revelation Biosciences, Inc. held a Special Meeting of Stockholders on March 18, 2026, where shareholders overwhelmingly approved Proposal 1 to authorize the issuance of common stock pursuant to Class J Common Stock Warrants (issued January 26, 2026) to exceed Nasdaq's 20% Exchange Cap, with 4,033,345 votes for, 104,162 against, and 34,228 abstentions out of 4,171,735 shares present (quorum met from 10,492,469 outstanding shares). Proposal 2 for discretionary adjournment also passed strongly (4,044,322 for, 92,422 against). Following approval, the warrants' expiration date extends to March 18, 2031.

• ·Definitive proxy statement filed with SEC on February 17, 2026
• ·Warrant inducement letter dated January 23, 2026
• ·No broker non-votes on either proposal
• ·Common stock par value $0.001 per share

19-03-2026

Occidental Petroleum's 2026 Proxy Statement highlights robust 2025 performance with $10.5B operating cash flow, $4.3B free cash flow before working capital, $575M reduction in capital and operating costs, record production, and company-record safety TRIR of 0.07, despite a more challenging commodity price environment YoY. Management reduced principal debt by $4B directly and an additional $7B via OxyChem divestiture proceeds, grew the resource base to 16.5B BOE from 8B in 2015, and increased dividends with a recent quarterly hike over 8% and 44% total rise since the 2023 CrownRock acquisition announcement. The annual meeting on May 1, 2026 seeks election of 10 directors, advisory approval of NEO compensation, and ratification of KPMG as auditor.

• ·Record date for annual meeting: March 10, 2026
• ·2026 Annual Meeting: May 1, 2026 at 9:00 a.m. Central Time via live webcast at www.virtualshareholdermeeting.com/OXY2026
• ·TRIR including OxyChem: 0.14 for FY 2025
• ·Proposals: Elect 10 directors, advisory vote on NEO compensation, ratify KPMG

19-03-2026

New Providence Acquisition Corp. III (NPACU), a SPAC, shared via social media on March 19, 2026, details of its proposed business combination with Abra Financial Holdings, Inc., pursuant to a Business Combination Agreement dated March 16, 2026, involving merger sub Aether Merger Sub I, Corp. The communication announces an upcoming Registration Statement on Form S-4, including a proxy statement/prospectus for SPAC shareholders, with standard advisories to review SEC filings for transaction details and risks. It emphasizes extensive forward-looking statement disclaimers and lists over 30 specific risks, including regulatory uncertainties in digital assets, potential failure to close, high transaction costs, and crypto market volatility.

• ·Commission File No.: 001-42610
• ·SPAC address: 401 S County Road #2588, Palm Beach, FL 33480
• ·IPO Prospectus filed with SEC on April 24, 2025

19-03-2026

RCI Hospitality Holdings, Inc. filed its 10-K reporting FY25 revenues of $279.4M, down 5.5% YoY from $295.6M, with Nightclubs segment nearly flat at $242.5M (-0.6% YoY) despite a 4.4% SSS decline in 4Q25, while Bombshells revenues plunged 29.2% YoY to $35.8M due to divestitures and 19.5% SSS drop. 4Q25 revenues fell 3.1% to $70.9M, with Adjusted EBITDA dropping to $52.6M from $72.6M YoY; however, net income attributable to common stockholders improved to $10.8M from $3.0M, supported by lower impairments and share repurchases reducing outstanding shares by 14% to 7.71M.

• ·Corporate expenses $15.4M in 4Q25 (21.8% of revenues) vs $7.1M (9.7%) YoY, driven by legal accrual.
• ·Impairments and other charges $3.7M in 4Q25 vs $10.1M YoY; FY25 $5.9M vs $36.6M.
• ·Free cash flow FY25 $45.4M vs $48.4M (flat).
• ·X Spaces call at 4:30 PM ET on March 19, 2026.

19-03-2026

Common and preferred shareholders of Nuveen Missouri Quality Municipal Income Fund (NOM), Nuveen Pennsylvania Quality Municipal Income Fund (NQP), and Nuveen Municipal High Income Opportunity Fund (NMZ) have approved a proposal to merge the funds. The shareholder meeting for Nuveen New Jersey Quality Municipal Income Fund (NXJ) has been adjourned to April 2, 2026, to allow for additional vote solicitation. This update was filed by NMZ under Rule 425 on March 19, 2026.

• ·Commission File No. for NMZ: 333-290590
• ·Commission File No. for NXJ: 811-09455

19-03-2026

BOK Financial Corporation's DEF 14A proxy statement, filed March 19, 2026, solicits votes for the virtual annual shareholder meeting on May 5, 2026, including electing 15 directors, ratifying Ernst & Young LLP as auditors for fiscal year ending December 31, 2026, and an advisory vote approving named executive officer compensation. George B. Kaiser, beneficial owner of 62.50% of outstanding shares, plans to vote all his shares in favor of the proposals. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Record date for shareholders entitled to vote: March 9, 2026
• ·Annual meeting: May 5, 2026, at 2:30 p.m. Central Time, virtual webcast at www.virtualshareholdermeeting.com/BOKF2026
• ·Principal executive offices: Bank of Oklahoma Tower, One Williams Center, Tulsa, OK 74172
• ·Annual Report to Shareholders for fiscal year ended December 31, 2025, enclosed with proxy materials

19-03-2026

Jackson Financial Inc. closed transactions on March 19, 2026, where Grand River Funding Trust I issued 500,000 2036 P-Caps for $500M and Grand River Funding Trust II issued 400,000 2056 P-Caps for $400M, creating on-demand capital facilities allowing the Company to issue up to $500M of 6.311% Senior Notes due 2036 (over 10 years) and $400M of 7.280% Senior Notes due 2056 (over 30 years). The Company pays semi-annual facility fees of 2.066% and 2.430% on unexercised portions, respectively, with mandatory exercises if consolidated net worth falls below $2.75B (adjusted for certain events). This structure enhances liquidity backed by U.S. Treasury strips, with P-Caps redeemable on Feb 15, 2036 and Feb 15, 2056.

• ·P-Caps issued in private placements under Rule 144A, held only by qualified institutional buyers that are also qualified purchasers under Investment Company Act.
• ·Issuance Rights exercisable over 10 years for 2036 Trust and 30 years for 2056 Trust; automatic exercise on facility fee payment failure (30-day cure) or Company bankruptcy events.
• ·Company right to redeem Senior Notes at greater of principal or make-whole price plus accrued interest; Trusts invested proceeds in principal and interest strips of U.S. Treasury securities.

19-03-2026

Humacyte, Inc. announced the pricing of a $20M registered direct offering of 25M shares of common stock, led by a new life science investor and a long-only mutual fund, with gross proceeds expected before deducting expenses. Net proceeds will fund Symvess commercialization in vascular trauma, a BLA supplement filing for hemodialysis including upcoming Phase 3 readout, pipeline development, and general corporate purposes. The offering is expected to close on or about March 20, 2026.

• ·Shelf registration statement (Form S-3 No. 333-290231) filed September 12, 2025, declared effective September 22, 2025
• ·United States commercial launch of Symvess commenced in Q1 2025
• ·Titan Partners acting as sole placement agent

19-03-2026

Baxter International Inc. filed an 8-K on March 19, 2026, under Items 7.01 and 9.01, furnishing a Stockholder Engagement Presentation (Exhibit 99.1) to certain stockholders as part of its stockholder engagement program. The information is not deemed filed under the Exchange Act unless expressly incorporated by reference. The filing was signed by Ellen K. Bradford, Senior Vice President and Corporate Secretary.

• ·Filing intended to satisfy Regulation FD Disclosure requirements.
• ·Registrant details: Delaware incorporation, Commission File Number 1-4448, IRS EIN 36-0781620, principal offices at One Baxter Parkway, Deerfield, Illinois 60015.

19-03-2026

Solid Biosciences Inc. filed an S-3 shelf registration on March 19, 2026, to allow selling stockholders to resell up to 14,973,257 shares of common stock issued at $5.61 per share and 27,807,482 shares underlying pre-funded warrants issued at $5.609 per warrant from a private placement closed on March 9, 2026. The company will not receive proceeds from these resales but bore registration costs; total shares outstanding were 98,391,314 as of March 10, 2026. Major institutional investors like Perceptive Life Sciences Master Fund (12.16% ownership prior) and others are listed as selling stockholders with beneficial ownership capped by 4.99%-9.99% limitations on warrant exercises.

• ·Private placement securities purchase agreement dated March 6, 2026.
• ·Pre-funded warrants exercisable immediately at $0.001 per share until fully exercised.
• ·Registration rights agreement requires filing within 30 days of private placement closing.

19-03-2026

HeartSciences Inc. filed definitive additional proxy materials (DEFA14A) on March 19, 2026, for its 2026 Annual Meeting of Shareholders on April 30, 2026 (virtual), soliciting votes on electing Andrew Simpson as Class III Director, approving an increase in shares under the 2022 Equity Incentive Plan (appears evergreen provision), amending the Certificate of Formation for officer exculpation under Texas law, ratifying Haynie & White LLP as independent auditors, and approving potential adjournment if needed. The Board recommends 'For' all proposals, with voting deadline April 29, 2026, 11:59 PM ET. No financial performance data or period comparisons disclosed.

• ·Annual Meeting: April 30, 2026, 10:00 AM EDT, virtual at https://meetings.lumiconnect.com/200-700-572-593
• ·Request proxy materials by April 16, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Fiscal year end: April 30; Incorporated in TX; Address: 550 Reserve St, Suite 360, Southlake, TX 76092

19-03-2026

On March 17, 2026, Darron M. Anderson, a Director on Tidewater Inc.'s Board and member of the Audit Committee and Safety & Sustainability Committee, notified the Board of his intent not to stand for reelection at the 2026 Annual Meeting of Stockholders. His decision did not result from any disagreement with the company's operations, policies, or practices, and he will continue in his role until the expiration of his current term. In connection with this, the Board size will be reduced from eight to seven Directors.

19-03-2026

CIMG Inc. reported Q3 FY2026 revenues of $15.8M, a staggering 68,970% YoY increase from $23k, with gross profit rising to $87k from $15k. However, the company incurred a significantly larger net loss of $19.4M versus $1.5M YoY, driven by a $17.5M fair value variation loss, while operating expenses increased 37% to $2.1M. Balance sheet showed total assets declining 9% QoQ to $67.4M from $74.2M, though stockholders' equity grew 22% to $56.5M amid share issuances totaling ~$29M.

• ·Cash used in operating activities increased to $8.5M from $1.3M YoY.
• ·Financing activities provided $8.5M net cash from stock issuances, warrants, and private placements.
• ·Digital assets increased QoQ to $64.0M from $57.0M, but fair value variation recorded a $17.5M loss.
• ·Basic and diluted loss per share improved to -$1.43 from -$3.42 YoY due to higher share count.
• ·Inventories dropped sharply QoQ to $157 from $11.9M.

19-03-2026

Skye Bioscience, Inc. received a Nasdaq deficiency notice on March 17, 2026, stating that its common stock (SKYE) closing bid price was below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5450(a)(1). The company has 180 calendar days until September 14, 2026, to regain compliance, potentially through a reverse stock split, with trading continuing uninterrupted for now. However, there is no assurance of compliance, and failure could lead to transfer or further review.

• ·Nasdaq deficiency letter issued by Nasdaq Listing Qualifications Department
• ·Compliance possible if bid price closes at $1.00 or more for 10 consecutive business days
• ·Reverse stock split, if implemented, must be completed no later than 10 business days before September 14, 2026
• ·Potential second 180-day compliance period if qualifying for Nasdaq Capital Market standards (except bid price)

19-03-2026

Director Dennis E. Murray, Jr. resigned from the Boards of Directors of Civista Bancshares, Inc. and Civista Bank on March 13, 2026, with no disagreement cited. Civista Bancshares is a $4.4B financial holding company headquartered in Sandusky, Ohio, with primary subsidiary Civista Bank operating 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky.

• ·Civista Bank founded in 1884.
• ·Civista Leasing and Finance Division headquartered in Pittsburgh, Pennsylvania.
• ·Common shares traded on NASDAQ under symbol CIVB.

19-03-2026

Niagen Bioscience, Inc. announced on March 19, 2026, that its Board approved an increase in the share repurchase program authorization from $10.0 million to $20.0 million to provide flexibility for returning capital to stockholders. Through March 17, 2026, the Company has repurchased approximately $2.6 million of its common stock. The program permits open market or private repurchases under Rule 10b-18 or 10b5-1 plans and remains in effect for the previously approved 24-month period unless modified.

• ·Previous share repurchase program approved by Board on October 31, 2025
• ·Repurchases subject to Rule 10b-18 and potentially Rule 10b5-1 trading plan
• ·Program may be suspended, modified, or terminated at Board's discretion

19-03-2026

Cintas Corporation filed a Form 425 communication on March 19, 2026, sharing letters and a video transcript from CEOs Todd Schneider (Cintas) and Steven S. Sintros (UniFirst) to UniFirst employees, expressing excitement about the pending merger announced last week and emphasizing cultural alignment between the companies founded by the Croatti and Farmer families. The message assures UniFirst team members of immediate integration as Cintas partners on day one post-close, with seniority honored for benefits like PTO, 401(k), and profit sharing, while highlighting the need for all UniFirst talent to serve an additional 300,000 customers. Extensive forward-looking statements outline risks including integration challenges, regulatory approvals, and economic factors that could impact the transaction.

• ·UniFirst employees will retain original start dates for all benefits purposes upon merger close.
• ·Cintas emphasizes need for UniFirst roles including RSRs, sales reps, divisional directors, and production staff.
• ·Communication addresses potential rumors and requests employees to 'give us a chance' amid integration challenges.

19-03-2026

Subsidiaries of CBL & Associates Properties Inc., including entities such as Cherryvale Mall, LLC, Kirkwood Mall Acquisition LLC, and others, entered into a Loan Agreement dated March 13, 2026, with Goldman Sachs Bank USA to finance multiple retail properties including Kirkwood Mall, Post Oak Mall, and Westmoreland Parcel. The agreement establishes cash management accounts, defeasance options, and various affirmative and negative covenants related to property maintenance, leasing, and financial reporting. No specific loan amounts or financial performance metrics are disclosed in the provided filing content.

• ·Filing Date: March 19, 2026
• ·Loan Agreement Effective Date: March 13, 2026
• ·SEC Items Reported: 1.01, 2.03, 8.01, 9.01
• ·Approved Property Manager: CBL & Associates Management, Inc.
• ·Schedules include Properties and Square Footage (Schedule A), Allocated Loan Amounts (Schedule G), and others

19-03-2026

Senti Biosciences, Inc. entered into a Lease Amendment effective September 1, 2025, reducing its leased space from 91,910 to 45,955 rentable square feet (50% reduction) and monthly base rent starting at $188,311, providing cost savings but reflecting facility downsizing. The Landlord will draw $2.0 million from the Company's $2.76 million letter of credit (reducing it to $760,000), and a $1.0 million Reduction Fee is payable; concurrently, the sublease with GeneFab, LLC was amended to match the reduced terms, with GeneFab's $1.374 million outstanding rent convertible to prepayment credits.

• ·Company remains responsible for 100% of building utilities until surrendered space is re-let.
• ·Outstanding GeneFab rent of $1.374M may be satisfied via prepayment credit for GeneFab services; unpaid portion due September 1, 2026.
• ·If $2.0M LOC drawn, Company gains equivalent prepayment credit from GeneFab starting September 1, 2026.

19-03-2026

Inhibrx Biosciences reported Q4 and FY 2025 financial results with significant YoY expense reductions, including R&D down 24% to $25.3M in Q4 (vs $33.4M) and 45% to $113.0M for FY (vs $203.7M), and G&A down 67% to $5.6M in Q4 (vs $16.7M) and 82% to $23.3M for FY (vs $127.9M), resulting in a narrower Q4 net loss of $32.8M ($2.11/share) versus $47.9M ($3.09/share). However, FY 2025 net loss widened to $140.1M ($9.04/share) from FY 2024 net income of $1.7B ($114.01 basic/share), reflecting the absence of the one-time $2.0B gain from the 101 Transaction, while cash stood at $124.2M (down 19% YoY) as of Dec 31, 2025, supplemented by $75M loan proceeds on March 18, 2026. The company highlighted upcoming milestones for ozekibart (INBRX-109) BLA submission in early Q2 2026 and data readouts for both ozekibart and INBRX-106.

• ·Long-term debt increased to $100.6M as of Dec 31, 2025 from $0 in 2024.
• ·Stockholders’ equity declined to $8.0M as of Dec 31, 2025 from $133.6M in 2024.
• ·Revenue was minimal at $1.3M for FY 2025 vs $0.2M in FY 2024.